Dishman Carbogen Amcis Expands ADC Manufacturing with CHF 25M Swiss Investment.

Dishman Carbogen Amcis upgrades Swiss sites with Japanese partner to produce ADC linkers. 850L reactors coming to Aarau/Neuland by 2027.

Strategic Expansion Highlights

💊 Focus Area: Antibody-Drug Conjugate (ADC) components
🇨🇭 Locations Upgraded:

  • Aarau Facility: 850L reactors + 0.4m filter dryers (Q1 2027)
  • Neuland Facility: Matching capacity (Q3 2027)
    🤝 Partnership: Long-standing Japanese pharma client co-investing

Technology & Capacity Boost

Key Infrastructure Additions

EquipmentSpecificationPurpose
850L ReactorsGMP-compliantLarge-scale linker synthesis
Agitated Filter Dryers0.4m capacityHigh-potency API handling
Containment SystemsADC-specificSafe cytotoxic compound processing

Market Context

📈 ADC Growth: Global market to reach $28B by 2030 (18% CAGR)
💉 Therapeutic Demand: 12+ FDA-approved ADCs in oncology
🇯🇵 Japan Focus: Major hub for ADC innovation (Daiichi Sankyo, Takeda)

Strategic Implications

For CARBOGEN AMCIS

🔬 Niche Leadership: Strengthens position as top-3 global ADC CMO
🔄 Supply Chain Security: Dual-site production ensures redundancy
🌍 Client Lock-in: Deepens partnership with anchor Japanese innovator

For Indian Parent

🇮🇳 Dishman Carbogen Benefits:

  • Revenue upside from Swiss subsidiary
  • Potential tech transfer to Indian facilities
  • Enhanced credibility for complex injectables

Investment Timeline

🗓️ 2021 Baseline: Bubendorf site extension (Phase 1)
🛠️ 2025-26: Equipment procurement/installation
🏭 2027: Full operational capacity

Leadership Insight

“This co-investment reflects our shared vision to dominate the ADC linker market with Swiss precision.”
– CARBOGEN AMCIS Management

“Our Swiss sites now offer end-to-end ADC capabilities from payload to conjugation.”
– Dishman Carbogen Spokesperson


Why This Matters?

🎯 Precision Medicine: Supports next-gen cancer therapies
⚗️ High-Potency Expertise: Positions Switzerland as ADC hub
🤝 Partnership Model: Blueprint for pharma-CMO collaboration

*Follows 2021 CHF 18M Bubendorf investment. Serves Top-10 pharma companies.* 💊🔬

Haldiram’s Expands Ready-to-Eat Empire with ₹662 Crore Noida Facility.

Scroll to Top